N/O-linked degrons and degronimers for protein degradation

Patent metadata

Field	Value
Publication number	US-12180225-B2
Application number	US-202217959144-A
Country	US
Kind code	B2
Filing date	Oct 3, 2022
Priority date	Jun 20, 2017
Publication date	Dec 31, 2024
Grant date	Dec 31, 2024

Abstract

This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.

First claim

We claim:

1. A compound of Formula:

or a pharmaceutically acceptable salt thereof;
wherein:
W 1 is C═O;
W 2 is C═O;
one X is NH and the other is CH 2 ;
n is 0, 1, 2, or 3;
R 1 is

R 2 is alkyl or hydrogen;
R 5 is selected at each instance from the group consisting of alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, azide, amino, cyano, —NH(alkyl), —N(alkyl) 2 , C(O)R 4 , haloalkyl, aryl, heteroaryl, and carbocyclic;
R 4 is selected at each instance from the group consisting of alkyl, alkenyl, alkynyl, hydroxyl, alkoxy, azide, amino, —NHalkyl, —N(alkyl) 2 , —NHSO 2 alkyl, —N(alkyl)SO 2 alkyl, —NHSO 2 aryl, —N(alkyl)SO 2 aryl, —NHSO 2 alkenyl, —N(alkyl)SO 2 alkenyl, —NHSO 2 alkynyl, —N(alkyl)SO 2 alkynyl, and haloalkyl;
R 10 and R 11 are hydrogen;
R 12 is Linker-H;
Linker is selected from the group consisting of:

wherein:
X 1 and X 2 are independently selected from the group consisting of bond, NH, NR 25 , CH 2 , CHR 25 , C(R 25 ) 2 , O, and S;
R 20 , R 21 , R 22 , R 23 , and R 24 are independently selected from the group consisting of bond, alkyl, —C(O)—, —C(O)O—, —OC(O)—, —C(O)alkyl, —C(O)Oalkyl, —SO 2 —, —S(O)—, —C(S)—, —C(O)NH—, —NHC(O)—, —N(alkyl)C(O)—, —C(O)N(alkyl)-, —O—, —S—, —NH—, —N(alkyl)-, —CH(—O—R 26 )—, —CH(—NHR 25 )—, —CH(—NH 2 )—, —CH(—NR 25 2 )—, —C(—O—R 26 )alkyl-, —C(—NHR 25 )alkyl-, —C(—NH 2 )alkyl-, —C(—NR 25 2 )alkyl-, —C(R 4 R 4 )—, -alkyl(R 27 )-alkyl (R 28 )—, —C(R 27 R 28 )—, —NHC(O)NH—, —N(R 25 )C(O)N(R 25 )—, —N(H)C(O)N(R 25 )—, alkenyl, haloalkyl, alkoxy, alkynyl, heteroarylalkyl, aryl, arylalkyl, heterocycle, heteroaryl, lactic acid, glycolic acid, carbocycle, —O—(CH 2 ) 1-12 —O—, —NH—(CH 2 ) 1-12 —NH—, —NH—(CH 2 ) 1-12 —O—, —O—(CH 2 ) 1-12 —NH—, —S—(CH 2 ) 1-12 —O—, —O—(CH 2 ) 1-12 —S—, —S—(CH 2 ) 1-12 —S—, —S—(CH 2 ) 1-12 —NH—, and —NH—(CH 2 ) 1-12 —S—;
each of which R 20 , R 21 , R 22 , R 23 , and R 24 is optionally substituted with one or more substituents selected from R 101 ,
R 101 is independently selected at each occurrence from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, hydroxyl, aryl, heteroaryl, heterocycle, arylalkyl, heteroarylalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, CN, —COOalkyl, COOH, NO 2 , F, Cl, Br, I, CF 3 , NH 2 , NHalkyl, and N(alkyl) 2 ;
R 25 is selected at each instance from the group consisting of alkyl, —C(O) H, —C(O)OH, —C(O)alkyl, —C(O)Oalkyl, alkenyl, and alkynyl;
R 26 is hydrogen, alkyl, arylalkyl, heteroarylalkyl, alkenyl, or alkynyl; and
R 27 and R 28 are independently selected from the group consisting of hydrogen, alkyl, and amine, or together with the carbon atom to which they are attached, form C(O), C(S), C═CH 2 , a C 3 -C 6 spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O, or form a 1 or 2 carbon bridged ring;
wherein:
heteroaryl is a 5- or 6-membered aryl ring system that contains 1, 2, or 3 heteroatoms selected from the group consisting of O, N, and S;
aryl is phenyl or naphthyl; and
heterocycle is a monocyclic 3- to 8-membered heterocycle or a bicyclic 5 - to 11-membered heterocycle, wherein heterocycle contains 1, 2, or 3 heteroatoms selected from the group consisting of O, N, and S.

2. The compound of claim 1 of formula:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 , wherein the Linker is selected from the group consisting of

4. The compound of claim 2 , wherein the Linker is selected from the group consisting of

5. The compound of claim 2 , wherein the Linker is selected from the group consisting of

6. The compound of claim 2 , wherein the Linker is selected from the group consisting of

7. The compound of claim 2 , wherein R 20 , R 21 , R 22 , R 23 , and R 24 are independently selected from the group consisting of bond, alkyl, —C(O)—, —C(O)O—, —OC(O)—, —C(O)alkyl, —C(O)Oalkyl, —C(O)NH—, —NHC(O)—, —N(alkyl)C(O)—, —C(O)N(alkyl)-, —O—, —NH—, —N(alkyl)-, —CH(—O—R 26 )—, —CH(—NHR 25 )—, —CH(—NH 2 )—, —CH(—NR 25 2 )—, —C(—O—R 26 )alkyl-, aryl, and heterocycle.

8. The compound of claim 2 , wherein R 20 , R 21 , R 22 , R 23 , and R 24 are not substituted.

9. The compound of claim 2 , wherein one of R 20 , R 21 , R 22 , R 23 , and R 24 is heterocycle.

10. The compound of claim 9 , wherein one of R 20 , R 21 , R 22 , R 23 , and R 24 is independently pyrrolidinyl, morpholinyl, piperazinyl, or piperidinyl.

11. The compound of claim 2 , wherein R 5 is selected at each instance from halogen.

12. The compound of claim 11 , wherein R 5 is fluorine.

13. The compound of claim 2 , wherein n is 0.

14. The compound of claim 2 , wherein n is 1.

15. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

17. A method for the treatment of a hematopoietic malignancy disorder comprising administering an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof to a patent in need thereof, wherein the hematopoietic malignancy disorder is selected from multiple myeloma, acute myelogenous leukemia or lymphoblastic leukemia.

18. The method of claim 17 , wherein the hematopoietic malignancy disorder is acute myelogenous leukemia or lymphoblastic leukemia.

19. The method of claim 17 , wherein the hematopoietic malignancy disorder is multiple myeloma.

Assignees

• C4 Therapeutics Inc

Inventors

• Phillips Andrew J
• Nasveschuk Christopher G
• Henderson James A
• Liang Yanke
• He Minsheng
• Duplessis Martin
• Chen Chi-Li

Classifications

• G07F17/3288

  Betting, e.g. on live events, bookmaking · CPC title

• G07F17/3272

  Games involving multiple players · CPC title

• G07F17/3246

  involving coins and/or banknotes · CPC title

• G07F17/3244

  Payment aspects of a gaming system, e.g. payment schemes, setting payout ratio, bonus or consolation prizes · CPC title

• G07F17/3225

  Data transfer within a gaming system, e.g. data sent between gaming machines and users · CPC title